By Andrew Scurria (January 23, 2014, 7:24 PM EST) -- The U.S. Food and Drug Administration on Thursday barred drug products from a Ranbaxy Laboratories Inc. manufacturing plant in India from the U.S. market, the sixth company facility found to fail good manufacturing standards.
The FDA prohibited Ranbaxy's Toansa, India, site from manufacturing active pharmaceutical ingredients for FDA-regulated products after officials uncovered "significant" violations of U.S.-promulgated manufacturing practices meant to ensure drug safety.
Topping the list was Ranbaxy employees' practice of retesting raw materials, intermediate drug products and finished APIs that failed to meet specifications until they obtained "acceptable" results. Ranbaxy workers did not report or investigate what caused these failures,...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!